Close

BIO Submits Comments Re: Medicare Program; Part B Drug Payment Model [CMS-1670-P]

The Biotechnology Innovation Organization appreciates this opportunity to submit comments on the Centers for Medicare and Medicaid Services’ proposed rule entitled Medicare Program; Part B Drug Payment Model...

Follow-Up on BIO’s Comments in Response to the ICER Value Framework

BIO’s comments to the USDA on the biomass crop assistance program enacted by the 2008 Farm Bill

Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.

BIO letter in support of H.R. 5418

To establish a pilot program for educating district court judges on patent related issues.

Cures Acceleration Network: Legislative Text

...

Small Business Early Stage Investment Program: Legislative Text

The Small Business Early Stage Investment Program would provide matching funds for investment companies who invest in small, high tech companies, including biotech firm.

Presentation: "Global Health Challenges: How Industry is Addressing Global Health", presented at the University of Virginia in June 2008

Global Health Challenges: How Industry is Addressing Global Health

Diran Makinde, Network Director, NEPAD Biosciences, West Africa Biosciences Network (WABNet), Senegal

Government's role in developing solutions for diseases that disproportionately affect developing countries

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH)

Mark Rohrbaugh, Director, Office of Technology Transfer, National Institutes of Health (NIH), US Department of Health & Human Services, USA

Ted Roumel, Vice President for Research Innovation & Commercialization at the University of Maryland Biotechnology Institute, USA

Innovation And The Global Research Enterprise WORLD HEALTH ORGANIZATION GENEVA—NOVEMBER 2007 THEODORE J. ROUMEL VICE PRESIDENT for RESEARCH, INNOVATION AND COMMERCIALIZATION UNIVERSITY OF MARYLAND BIOTECHNOLOGY INSTITUTE